Phase I Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor for Relapsed CD30+ Hodgkin's Lymphoma and CD30+ Non-Hodgkin's Lymphoma (CART CD30)
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 08 Mar 2017
At a glance
- Drugs CART 30 (Primary)
- Indications Hodgkin's disease; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- Acronyms CART-CD30
- 07 Jun 2017 Biomarkers information updated
- 02 Mar 2017 Planned End Date changed from 1 Dec 2032 to 1 Dec 2031.
- 08 Dec 2015 Results (n=9) presented at the 57th Annual Meeting and Exposition of the American Society of Hematology.